Clinical trials: Active Plaque Psoriasis
Psoriasis
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
To evaluate the efficacy and to compare efficacy and safety of BI 695501 versus Humira in patients with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT02850965
- Testing
- BI 695501, Humira
- Where
- 54 sites in United States, Czechia and 6 more
- Volunteers
- 318 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis
This is a Phase I dose escalation study to assess the safety, tolerability and activity of three different strengths of topical KX01 in the treatment of patients with plaque-type psoriasis.
- Trial name
- NCT05522816
- Testing
- KX01 0.01% (0.1 mg/g), KX01 0.1% (1.0 mg/g), KX01 1% (10 mg/g) for 5 days
- Volunteers
- 28 people
- Sponsor
- PharmaEssentia
Psoriasis
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
This double-blind, placebo-controlled study will be conducted at 5 study centers in the United States. Approximately 30 subjects with moderate to severe plaque-type psoriasis will take part.
- Trial name
- NCT01154101
- Testing
- SRT2104
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sirtris, a GSK Company
Psoriasis
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
This study is a multicenter, randomized, double-blind, placebo- and active-controlled Phase III clinical trial sponsored by Nanjing Shunxin Pharmaceutical Co., Ltd., a subsidiary of Chiatai Tianqing Pharmaceutical Group.
- Trial name
- NCT07724366
- Testing
- TQH3906 capsules, Deucravacitinib tablets 6 mg
- Where
- 45 sites in China
- Volunteers
- 400 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Plaque Psoriasis, Psoriasis
Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects
Study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effect of JTE-451 administered for 4 weeks in subjects with active plaque psoriasis.
- Conditions
- Plaque Psoriasis, Psoriasis, Skin Diseases
- Trial name
- NCT03018509
- Testing
- JTE-451
- Where
- 5 sites in Canada
- Volunteers
- 47 people
- Sponsor
- Shionogi Inc.
Active Plaque Psoriasis
Study to Assess VB-201 in Patients With Psoriasis
The purpose of this study is to examine the efficacy, safety and tolerability of VB-201 as compared with placebo on measures of disease activity in patients with psoriasis.
- Trial name
- NCT01001468
- Testing
- VB-201
- Where
- 18 sites in United States, Germany and 1 more
- Volunteers
- 185 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics